J&J guns for quick drug OK in lung cancer niche, taking the first step challenging AstraZeneca in EGFR
J&J has leapt straight from a Phase I trial to a BLA for amivantamab, a bispecific antibody designed to treat a subset of metastatic non …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
